These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 19236279)

  • 21. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.
    Marais DJ; Passmore JA; Denny L; Sampson C; Allan BR; Williamson AL
    J Med Virol; 2008 Jun; 80(6):953-9. PubMed ID: 18428143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus and genital cancer.
    Rapose A
    Indian J Dermatol Venereol Leprol; 2009; 75(3):236-43; quiz 243-4. PubMed ID: 19439875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clustering patterns of human papillomavirus genotypes in multiple infections.
    Spinillo A; Dal Bello B; Alberizzi P; Cesari S; Gardella B; Roccio M; Silini EM
    Virus Res; 2009 Jun; 142(1-2):154-9. PubMed ID: 19428748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics.
    Skjeldestad FE; Mehta V; Sings HL; Øvreness T; Turpin J; Su L; Boerckel P; Roberts C; Bryan J; Jansen KU; Esser MT; Liaw KL
    Acta Obstet Gynecol Scand; 2008; 87(1):81-8. PubMed ID: 17943470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervical cancer vaccination indications, efficacy, and side effects.
    Bayas JM; Costas L; Muñoz A
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S11-4. PubMed ID: 18586311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty.
    Van de Velde N; Brisson M; Boily MC
    Am J Epidemiol; 2007 Apr; 165(7):762-75. PubMed ID: 17276976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-HPV vaccination: preventing cervical cancer].
    Simon P; Dupond I
    Rev Med Brux; 2006 Sep; 27(4):S338-40. PubMed ID: 17091900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
    ; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
    Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial lessons learned in HPV vaccination.
    Herzog TJ; Huh WK; Downs LS; Smith JS; Monk BJ
    Gynecol Oncol; 2008 May; 109(2 Suppl):S4-11. PubMed ID: 18482557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines for the prevention of human papillomavirus infections.
    Speck LM; Tyring SK
    Skin Therapy Lett; 2006; 11(6):1-3. PubMed ID: 16912836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Harnessing the power of prevention: human papillomavirus vaccines.
    Mayeaux EJ
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New advances in vaccine technology and improved cervical cancer prevention.
    Huh WK; Kendrick JE; Alvarez RD
    Obstet Gynecol; 2007 May; 109(5):1187-92. PubMed ID: 17470604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.